<DOC>
	<DOCNO>NCT01680978</DOCNO>
	<brief_summary>A single center , double-blind , placebo-controlled , randomize , crossover , phase II study ass effect aleglitazar cardiac energetics function patient uncomplicated type 2 diabetes mellitus history coronary artery disease drug-naïve treat stable metformin . Eligible patient receive either 150 mcg aleglitazar placebo orally daily 6 week . After washout period 6 week , patient cross treatment yet receive .</brief_summary>
	<brief_title>A Study Evaluate Effect Aleglitazar Cardiac Energetics Function Patients With Type 2 Diabetes Mellitus History Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Adult patient , 40 70 year age ( inclusive ) screen Patients Type 2 diabetes mellitus diagnose least 12 week screen either drugnaïve treat stable metformin monotherapy least 12 week prior screen HbA1c &gt; /= 7 % &lt; /= 9 % screen Absence history coronary artery disease Diagnosis history Type 1 diabetes mellitus , diabetes result pancreatic injury , secondary form diabetes Current treatment fibrates , thiazolidinediones , insulin Prior intolerance thiazolidinediones and/or fibrates Clinically significant liver disease impair liver function Know chronic diabetic complication ( i.e . retinopathy , neuropathy , nephropathy ) Symptomatic congestive heart failure classify NYHA class IIIV Diagnosed and/or treated malignancy within past 5 year , except treat basal cell skin cancer , situ carcinoma cervix , situ prostate cancer Contraindications MRI , inability tolerate MRI scanning</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>